Foundayo is now available at Solira

Ordering for Foundayo (orforglipron) is now open at Solira. Foundayo received its UK marketing authorisation on 10 August 2026, and supply now follows an online weight-management consultation reviewed personally by our pharmacist.

What Foundayo is

Foundayo is a once-daily oral GLP-1 medicine from Eli Lilly. Unlike the peptide GLP-1 medicines, it is a small molecule, so it survives digestion without any fasting rules. You take one tablet at any time of day, with or without food or water, swallowed whole and never split, crushed or chewed. It is licensed for weight management in adults with a BMI of 30 or above, or 27 to 30 with a weight related condition, and for blood sugar control in type 2 diabetes.

How supply works at Solira

You complete an online weight-management consultation, and your answers, measurements and photographs are reviewed by a UK registered pharmacist. Where treatment is clinically appropriate, we arrange a short video call before your first supply, then your medicine is dispensed from our GPhC registered pharmacy and sent by Royal Mail Tracked 48, which is £3.99. There is no consultation fee, no prescription fee and no subscription.

Prices per 30-day supply

Every pack contains 30 film-coated tablets, which is 30 days of once-daily treatment. Prices include VAT. New patients start at 0.8mg, and each dose step lasts a minimum of 30 days before any increase is considered, up to a maximum of 17.2mg once daily. Not everyone needs the top dose. The aim is the lowest dose that gives steady, sustainable results, and each increase is reviewed with you.

Safety in short

The most common side effects are nausea, vomiting, diarrhoea and constipation, usually in the first weeks and after each dose increase. Smaller meals and good hydration help. Seek urgent medical help for severe persistent stomach pain, sudden vision loss or a loss of part of your vision, right-sided stomach pain with fever or yellowing of the skin, or if you cannot keep fluids down. Oral hormonal contraception may be less effective, so a non-oral method or an added barrier method is advised for 30 days after starting and for 30 days after each dose increase. Tell your pharmacist about every medicine you take, as some interact and need review.

Foundayo carries a black triangle. Please report any suspected side effect through the MHRA Yellow Card scheme.

References

• Foundayo (orforglipron) UK Summary of Product Characteristics.
• MHRA authorisation announcement, 10 August 2026.
• ATTAIN-1, New England Journal of Medicine, 2025.

Reviewed by Jimah Alsaai MPharm, GPhC 2232652, Superintendent Pharmacist, Solira. Last updated 28 August 2026.